Should a 74-year-old woman with chronic kidney disease stage 3, peripheral vascular disease with claudication, and taking famotidine, sertraline, vitamin D3, allopurinol, folic acid, atorvastatin, naftidrofuryl, losartan, amlodipine, aspirin, salbutamol, and Trimbow require a bone mineral density (DEXA) scan?

Yes, This 74-Year-Old Woman Meets Criteria for DEXA Scan

This patient absolutely qualifies for osteoporosis screening with DEXA scan based on age alone—the 2025 USPSTF guidelines recommend screening all women ≥65 years, and at 74 years old, she falls squarely within this recommendation 1.

Primary Indication: Age-Based Screening

• Universal screening threshold: All women aged 65 years or older should undergo bone mineral density screening with DXA (dual-energy X-ray absorptiometry) to prevent osteoporotic fractures 1
• This is a Grade B recommendation, meaning there is high certainty of moderate net benefit or moderate certainty of moderate-to-substantial benefit
• No additional risk factors are required at this age—age alone is sufficient justification

Additional Risk Factors Present

While age alone justifies screening, this patient has multiple additional risk factors that further strengthen the indication:

CKD Stage 3

• CKD is associated with mineral and bone disorder (CKD-MBD), which significantly increases fracture risk 2
• DXA predicts fractures in CKD patients with comparable accuracy to the general population 2
• WHO T-scores from DXA predict fracture risk similarly in patients with and without CKD 2
• CKD patients have altered bone turnover, mineralization defects, and increased cardiovascular calcification—all contributing to skeletal fragility

Medication Considerations

Several of her medications warrant attention:

• Losartan (RAAS inhibitor): Part of her CKD management, but RAAS dysregulation in CKD contributes to bone disease 3
• Atorvastatin: While primarily for cardiovascular risk, no direct bone-protective effect documented 4
• Sertraline (SSRI): SSRIs are associated with increased fracture risk in older adults, though not explicitly contraindicated 5
• Vitamin D3 1,000 IU daily: Appropriate supplementation, though the 2025 USPSTF draft recommends against vitamin D supplementation specifically for fracture prevention in community-dwelling adults ≥60 years 1. However, in CKD, vitamin D management is part of CKD-MBD treatment strategy 2, 3

Peripheral Vascular Disease with Claudication

• Reflects systemic atherosclerosis and reduced mobility
• Reduced physical activity/mobility is a known fracture risk factor
• Vascular disease and bone disease share common pathophysiology in CKD 6, 7

Practical Implementation

Order central DXA scanning of:

• Hip (femoral neck and total hip)
• Lumbar spine (L1-L4)

Do NOT use:

• Peripheral DXA
• Quantitative ultrasound
• Other alternative modalities

Central DXA is the established standard, correlates with bone strength and fracture outcomes, and was used in nearly all pharmacotherapy trials 1.

Screening Interval Considerations

• First-time screening: Proceed immediately given her age
• Rescreening interval: Evidence is limited, but generally:
  • If normal BMD: consider rescreening in 2-5 years
  • If osteopenia: consider rescreening in 1-2 years
  • If osteoporosis: initiate treatment and monitor response 1

CKD-Specific Monitoring Beyond DEXA

Given her CKD stage 3, comprehensive bone health assessment should include:

• Parathyroid hormone (PTH) levels—critical for CKD-MBD management 2
• Serum calcium and phosphorus—part of integrative CKD-MBD strategy 2
• 25-hydroxyvitamin D levels—to guide vitamin D repletion 2, 3
• Bone-specific alkaline phosphatase—if osteomalacia suspected 2

Common Pitfalls to Avoid

1. Do not delay screening thinking additional risk stratification is needed—age ≥65 is sufficient
2. Do not use FRAX alone without DXA in this patient—while FRAX can be used when DXA unavailable, it may underestimate risk in CKD 2
3. Do not assume vitamin D supplementation alone prevents fractures—the evidence does not support this for primary prevention 1
4. Do not ignore CKD-MBD management—DEXA is one component; PTH, calcium, phosphorus monitoring are equally important 2
5. Do not use bolus vitamin D dosing—steady-state dosing is preferred, especially in CKD 3

Treatment Implications

If DEXA reveals osteoporosis or high fracture risk:

• Bisphosphonates remain first-line in most cases, but require dose adjustment for CKD stage 3 8
• Denosumab does not require renal dose adjustment and may be preferred in advanced CKD
• Avoid high-dose calcium supplementation (USPSTF recommends against ≤1000 mg calcium for fracture prevention) 1
• Optimize CKD-MBD parameters (PTH, calcium, phosphorus) as part of integrated bone health strategy 2

Bottom line: Order the DEXA scan now. This patient meets clear guideline criteria, and the results will inform both osteoporosis management and broader CKD-MBD treatment strategy.